Cortex Discovery is involved in drug development and discovery, utilizing a deep-learning model to predict therapeutic effects, off-target effects, and pharmacological properties.

Cortex Discovery

OpenEye Scientific develops molecular modeling software and provides consulting services for drug discovery. The company focuses on computational molecular design and offers a range of tools for biopharmaceutical research.

OpenEye Scientific

Primordial AI utilizes evolutionary data and artificial intelligence to discover drug targets, focusing on achieving next-generation drug development.

Primordial AI

Cortex Discovery | 299 followers on LinkedIn. Novel applications of Artificial Intelligence for preclinical drug discovery. | Cortex Discovery’s in silico drug discovery platform is based on its leading-edge AI technology which can predict molecule properties in all therapeutic fields. The accuracy of its predictions has been validated in the lab, and rivals that of experiments.

Cortex is also developing a next-generation molecular docking technology, which combines deep learning with quantum molecular simulations to deliver unparalleled accuracy and speed when exploring new targets.

Computational Chemist

Gaspar Pinto

Machine Learning Research @ Cortex Discovery

Vladimir Chorošajev

Co-Founder, Cortex Discovery

Cédric Bény

Cortex Discovery is thrilled to announce our collaboration with Mcule , a leading molecule provider. Using Cortex's cutting-edge deep learning technology, we have predicted ADMET properties for the entire Mcule In Stock library of nearly 6 million compounds. Our advanced algorithms have helped annotate these compounds with critical physicochemical and ADMET properties, streamlining the drug discovery process. This collaboration brings together the power of Cortex's predictive modeling and Mcule’s extensive compound catalog, empowering researchers and accelerating the path from hit identification to lead optimization. Key Features: Aqueous solubility, permeability, and cytotoxicity insights CYP19A1 and hERG inhibition data Ready-to-order compounds from over 110 suppliers Stay tuned for more updates as we push the boundaries of preclinical drug discovery together! https://lnkd.in/dPceH7Vc #DrugDiscovery #CortexDiscovery #Mcule #AI #ADMET #virtualADMET #HitDiscovery #LeadOptimization

Mcule In-stock Database has been enhanced with predicted advanced pharmacological data generated by Cortex Discovery . Nearly 6M in-stock compounds annotated with numerous physicochemical and ADMET properties, such as water or DMSO solubility, PAMPA permeability, and toxicity are now available for download! Read more about the annotated properties from here: https://lnkd.in/dcE7spjK #collaboration #partnership #mculelibraries #cortexdiscovery #admet #virtualscreening

Mcule

Novel Antivirals Discovered in Collaboration with Stanford University We are proud to announce further progress at Cortex! Following the discovery of patent-pending antivirals against SARS-CoV-2 in collaboration with Aarhus University , Denmark - Published in Antiviral Research - our AI model has once again proven its effectiveness. This time, in partnership with Stanford University ’s Shirit Einav virology lab, we’ve identified two more antiviral agents using a different in vitro validation method. These advancements highlight our ongoing commitment to harnessing AI for impactful health solutions. We extend our gratitude to both Stanford and Aarhus ( David Olagnier and Demi van der Horst, PhD ) Universities for their crucial roles in these exciting developments. Stay tuned for more updates as we continue to innovate and expand our research! https://lnkd.in/deYZmme7 #CortexDiscovery #StanfordUniversity #AarhusUniversity #AI #deeplearning #virtualHTS #VirtualScreening #COVID19 #Virology

Dr. Ivan De Weber, PhD

Our AI Breakthrough in Antiviral Discovery Now Published! I'm excited to share that our latest research has been published in Antiviral Research! This work presents Cortex Discovery AI platform, and shows how the use of its virtual high-throughput screening (HTS) and virtual ADMET capabilities, has led to efficient drug discovery. Out of 6 compounds tested, 5 showed efficacy against SARS-CoV-2 in infected cells, with 2 now patented working prior and after COVID infection in 3D human cell cultures. Special thanks to Demi van der Horst, PhD and David Olagnier from Aarhus University for their outstanding work on the experiments and to our funders, notably CNRS , Novonordiskfonden and Lundbeckfonden. https://lnkd.in/dhkgTT2E Follow us for updated news in the AI-driven development of novel longevity compounds! #CortexDiscovery #AI #COVID #SARSCoV2 #AntiviralResearch #DrugDiscovery #VirtualHTS #VirtualADMET #Innovation #Patents #AarhusUniversity #CNRS

Further Proof of Cortex AI's Capabilities: Novel Anti-HIV Inhibitors Discovered Cortex Discovery is excited to announce another significant achievement in our quest to harness AI for groundbreaking drug discovery. Our AI model, initially trained on a PubChem assay for gp41 (HIV-1) inhibitors, has led to the discovery of novel anti-HIV inhibitors. In collaboration with Centre for Molecular Medicine Norway (NCMM), University of Oslo and SINTEF , we conducted an in vitro screen of gp41 inhibition from a library of 2000 new compounds. The top 10% of our in vitro ranking contained 21 of the total 22 hits, and 2 of our top 3 compounds were confirmed hits. This demonstrates the power of our technology for virtual HTS, showing that we can extend any HTS to a virtual HTS with comparable precision. Read more about our findings: gp41 Preclinical Candidates https://lnkd.in/dMxF-Pn4 #CortexDiscovery #SINTEF #deeplearning #virtualHTS #VirtualScreening #HIV #DrugDiscovery

Had a fantastic time at #NLSD2024 ! It was a pleasure meeting so many innovative minds and discussing the future of AI in drug discovery. I'm excited about the potential collaborations ahead and look forward to turning these great conversations into impactful partnerships, notably Keith Payne from Oncodesign Services , Haraldur Þorsteinsson from 3Z Pharmaceuticals , Maija Alakarjula from Admescope , Anna Erkstam from BioReperia , Joseph Zolnerciks, Ph.D. from Charles River Laboratories , Anders Malarstig from Pfizer , Robert Smith from Conscious Capital® , Katherina Orellana from Axxam , Agne Vaitkeviciene from Cureline Baltic , and Sebastian Soidinsalo from Polku Therapeutics . #CortexDiscovery #AI #DrugDiscovery #Collaboration #Innovation #LifeSciences #NLSD

Exciting AI-Driven Innovation for Drug Discovery at NLSD: I’m thrilled to introduce Cortex Discovery 's cutting-edge deep learning technology, which predicts molecular properties with accuracy that rivals experimental methods. Validated across multiple therapeutic areas, this innovation has led to new preclinical leads at negligible cost. We offer a wide range of services including: 🔹 Virtual High Throughput Screening 🔹 ADMET & off-target predictions 🔹 Virtual hit analog identification 🔹 De novo compound creation Our extensive libraries—ranging from FDA-approved to novel compounds—enable fast compound ordering. We specialize in seamless CRO collaborations, and can handle hit discovery and lead optimization in a single process. Next-gen Molecular Docking: Our new prototype, combining deep neural networks and molecular simulations (ultimately reaching the quantum level), allows for the fast exploration of new targets even without activity data, delivering unprecedented prediction accuracy—1000x faster than available alternatives. We are also partnering with leading labs to advance compounds for age-related disorders and life extension. Notably, we developed the first AI-discovered drug that extended lifespan in C. elegans by 33%. I would be happy to meet and discuss collaboration opportunities at NLSD! #AI #DrugDiscovery #virtualHTS #VirtualADMET #LifeExtension #Oncology #DeepLearning #Biotech #NLSD2024 #CortexDiscovery

The Aging Research & Drug Discovery Meeting event was a fantastic experience for us at Cortex Discovery ! It was great to reconnect with collaborators like Brian Kennedy from Ora Biomedical, Inc. , where we tested our first AI-generated compounds that enhance the lifespan of worms, and to discuss our ongoing work on #mTOR inhibitors with Singapore University. I also enjoyed catching up with the Rejuve.Bio team, including Dr. Axel Schumacher and Kennedy Schaal , who will be testing some of our new compounds on #Drosophila . We are excited about the opportunity to test senolytics with Kotb Abdelmohsen from the National Institute on Aging (NIA) . It was also productive to brainstorm potential collaborations with innovators like Yuta Lee , founder & CEO of ACCELERATED BIOSCIENCES CORP. Additionally, I learned about some fascinating new science from Léo Pio-Lopez at Tufts University , who is pioneering work on bioelectric-triggered regeneration applied to aging. Stay tuned for more updates on our upcoming longevity compounds here at Cortex Discovery ! https://agingpharma.org/ https://lnkd.in/dyFuaEGx #CortexDiscovery #AgingResearch #DrugDiscovery #AI #Longevity #Biotech #VirtualScreening #ARDD

First AI-Discovered Drug to Extend Lifespan in a Whole Organism Cortex Discovery is thrilled to announce the first compound discovered by AI that extends the lifespan of a whole organism: C. elegans. The new molecule increased the median lifespan of the worms by over 33%. Our team achieved this breakthrough using Cortex’s deep learning-based QSAR model trained on human mTOR inhibition data. The experiment was performed by Ora Biomedical, Inc. , a biotech co-founded by Brian Kennedy & Matt Kaeberlein and led by Mitchell Lee which specializes in longevity intervention, discovery and validation. Stay tuned as we continue advancing AI and longevity science! #AI #Longevity #Biotech #CortexDiscovery #Breakthrough #LifespanExtension #DrugDiscovery

Cortex AI-powered platform finds compounds killing cancer cells. We're excited to share a milestone achievement from Cortex Discovery! In a collaborative effort with Prof. Kaylene Simpson, Head of the Victorian Centre for Functional Genomics at Peter MacCallum Cancer Centre, Australia, we demonstrated that our AI-powered platform can successfully predict specific toxicity to cancer cells. Our innovative approach involved testing our predictions against a set of withheld compounds (unpublished data hidden from us), ensuring an unbiased validation. The results were outstanding, with an accuracy on par with experimental reproducibility. https://lnkd.in/dpAN7CJy #CortexDiscovery #PeterMacCallumCancerCentre #deeplearning #virtualHTS #VirtualScreening #CancerResearch

Metric
Company Name	Cortex Discovery	OpenEye Scientific	Primordial AI
Symbol
MSH ID	COM:CORTEXDISCOVERY	COM:EYESOPEN	COM:PRIMORDIALBIO
Market	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Pharmaceuticals	Biotechnology	Biotechnology
Country	DE	US	US
Stage
Employee Count
Website	cortexdiscovery.com	eyesopen.com	primordialbio.com
LinkedIn	cortex-discovery	openeye-scientific-software	primordial-ai
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic		43
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

CORT

COM:CORTEXDISCOVERY

Cortex Discovery

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue